FY2027 EPS Forecast for Gilead Sciences Lifted by Analyst

Gilead Sciences, Inc. (NASDAQ:GILD) – Research analysts at Erste Group Bank boosted their FY2027 earnings estimates for Gilead Sciences in a research report issued to clients and investors on Thursday, October 8th. Erste Group Bank analyst H. Engel now anticipates that the biopharmaceutical company will earn $9.90 per share for the year, up from their previous estimate of $9.88. The consensus estimate for Gilead Sciences’ current full-year earnings is ($0.47) per share.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. The business had revenue of $7.80 billion for the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The company’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.01 EPS.

Other equities research analysts have also issued research reports about the stock. Truist Financial raised their price target on shares of Gilead Sciences from $150.00 to $158.00 and gave the company a “buy” rating in a research note on Wednesday, October 7th. Wall Street Zen raised Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. Zacks Research downgraded Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 29th. HSBC boosted their price objective on Gilead Sciences from $155.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Finally, Morgan Stanley decreased their price objective on Gilead Sciences from $165.00 to $163.00 and set an “overweight” rating for the company in a report on Wednesday, October 7th. Twenty-three investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $159.33.

Gilead Sciences Trading Down 0.5%

Gilead Sciences stock opened at $150.43 on Tuesday. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The firm has a 50-day moving average price of $145.51 and a two-hundred day moving average price of $136.80. The firm has a market capitalization of $186.53 billion, a price-to-earnings ratio of -56.34 and a beta of 0.31. Gilead Sciences has a 52-week low of $114.02 and a 52-week high of $157.29.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th were issued a $0.82 dividend. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.2%. Gilead Sciences’s dividend payout ratio is presently -122.85%.

Insiders Place Their Bets

In related news, CFO Andrew Dickinson sold 3,000 shares of the stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $145.29, for a total value of $435,870.00. Following the completion of the transaction, the chief financial officer owned 164,096 shares in the company, valued at $23,841,507.84. This represents a 1.80% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 15,000 shares of the firm’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $147.90, for a total transaction of $2,218,500.00. Following the transaction, the chief executive officer directly owned 566,683 shares in the company, valued at approximately $83,812,415.70. The trade was a 2.58% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 105,000 shares of company stock valued at $14,940,540. Corporate insiders own 0.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in GILD. Persistent Asset Partners Ltd bought a new stake in shares of Gilead Sciences in the 2nd quarter worth $25,000. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at $25,000. Kimelman & Baird LLC acquired a new stake in shares of Gilead Sciences in the second quarter valued at $25,000. Wealth Preservation Advisors LLC lifted its holdings in shares of Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 81 shares during the period. Finally, Toth Financial Advisory Corp boosted its stake in Gilead Sciences by 85.5% during the third quarter. Toth Financial Advisory Corp now owns 217 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 100 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. Its research and commercial activities focus primarily on virology, including HIV, hepatitis B and hepatitis C, as well as oncology, inflammation and other areas of significant unmet medical need.

Gilead’s portfolio includes HIV treatments such as Biktarvy, Descovy, Genvoya and Sunlenca; hepatitis therapies including Epclusa, Harvoni and Vemlidy; and Veklury (remdesivir), an antiviral used to treat COVID-19 in certain patients.